Curaleaf (OTCMKTS:CURLF) Announces Quarterly Earnings Results

Curaleaf (OTCMKTS:CURLF) issued its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03, Zacks reports. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%.The company had revenue of $333.07 million during the quarter, compared to analysts’ expectations of $328.70 million.

Curaleaf Stock Down 1.9%

Shares of OTCMKTS CURLF opened at $2.43 on Friday. Curaleaf has a 12-month low of $0.68 and a 12-month high of $5.05. The firm’s 50-day simple moving average is $2.51 and its 200 day simple moving average is $2.70. The company has a quick ratio of 0.71, a current ratio of 1.47 and a debt-to-equity ratio of 0.96. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -7.60 and a beta of 0.74.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CURLF. Alliance Global Partners reiterated a “buy” rating on shares of Curaleaf in a research report on Monday, December 22nd. ATB Cormark Capital Markets raised shares of Curaleaf to an “outperform” rating in a research note on Tuesday, December 2nd. Finally, Zacks Research raised shares of Curaleaf from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy”.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.